Minerva Neurosciences, Inc. (NERV)
$4.89-$0.24 (-4.68%) Today
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
https://www.minervaneurosciences.comSEC filings for NERV on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 8 | 2,632,847 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
18 Form 4 filings on record, the earliest from Dec 6, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Inderjit Kaul - Director | Grant or award | Stock Option (right to buy) | 12,147 | $0.00 | - | |
| Frederick W. Ahlholm - Officer | Grant or award | Employee Stock Option (right to buy) | 680,000 | $0.00 | - | |
| Remy Luthringer - Officer | Grant or award | Employee Stock Option (right to buy) | 1,690,700 | $0.00 | - | |
| Fouzia Laghrissi-Thode | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| David Kupfer | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Inderjit Kaul | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Heek G. Jan van | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Hans Peter Hasler | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| James Joseph O'Connor - Officer | Grant or award | Employee Stock Option (right to buy) | 350,800 | $0.00 | - | |
| Inderjit Kaul | Grant or award | Stock Option (right to buy) | 12,169 | $0.00 | - | |
| Inderjit Kaul | Grant or award | Stock Option (right to buy) | 9,500 | $0.00 | - | |
| Hans Peter Hasler | Grant or award | Stock Option (right to buy) | 12,500 | $0.00 | - | |
| Fouzia Laghrissi-Thode | Grant or award | Stock Option (right to buy) | 12,500 | $0.00 | - | |
| Frederick W. Ahlholm - Officer | Grant or award | Employee Stock Option (right to buy) | 47,500 | $0.00 | - | |
| Remy Luthringer - Officer | Grant or award | Employee Stock Option (right to buy) | 105,000 | $0.00 | - | |
| Geoff Race - Officer | Grant or award | Employee Stock Option (right to buy) | 95,000 | $0.00 | - | |
| Heek G. Jan van | Grant or award | Stock Option (right to buy) | 12,500 | $0.00 | - | |
| David Kupfer | Grant or award | Stock Option (right to buy) | 12,500 | $0.00 | - |
Minerva Neurosciences, Inc. (NERV) had 8 insider filings in the last 90 days, with the most recent on 2026-08-03. The full record for NERV runs to 18 Form 4 filings, the earliest from 2024-12-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of NERV were filed in the last 90 days.
No insider sales of NERV were filed in the last 90 days.
This page tracks NERV Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NERV to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
